Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

GlaxoSmithKline plc (ADR) (GSK), Sarepta Therapeutics Inc (SRPT): Could This DMD Treatment Become a Blockbuster Drug?

Duchenne muscular dystrophy, or DMD, is a muscle-wasting disease caused by a genetic mutation in the dystrophin gene — the largest gene on the X chromosome — which affects one in every 2,400 male births. Muscle weakness in DMD patients generally spreads from the legs to the pelvis, eventually reaching the arms, neck, and other areas, confining most patients to a wheelchair by age 12 and resulting in a maximum lifespan of around 25 years.

To date, there is no effective treatment for DMD, but there could be soon, thanks to three biotech companies: Sarepta Therapeutics Inc (NASDAQ:SRPT), Prosensa Holding NV, and GlaxoSmithKline plc (ADR) (NYSE:GSK). However, Sarepta Therapeutics Inc (NASDAQ:SRPT) recently took the lead after Prosensa, which is partnered with GlaxoSmithKline plc (ADR) (NYSE:GSK), reported disappointing clinical trial data for its DMD treatment. Could Sarepta Therapeutics Inc (NASDAQ:SRPT)’s treatment finally be the game-changing, blockbuster drug that DMD patients have been waiting for?

GlaxoSmithKline plc (ADR) (NYSE:GSK)

Sarepta gains the upper hand
Prosensa and GlaxoSmithKline plc (ADR) (NYSE:GSK)’s co-developed DMD treatment, drisapersen, is intended to increase the production of dystrophin, a protein that facilitates muscle growth that is absent in DMD patients. GSK and Prosensa recently released the eagerly anticipated results from drisapersen’s phase 2 trials that concluded a year ago, but the results were fairly disappointing.

Drisapersen was shown to produce dystrophin in 72% of patients on a continuous dose, and in 59% of those who had intermittent doses of the drug. By comparison, Sarepta Therapeutics Inc (NASDAQ:SRPT)’s competing drug, eteplirsen, showed a 100% success rate in increasing the dystrophin production rate in all dosed patients. Both drisapersen and eteplirsen are genetic treatments that work at the RNA level to modify dystrophin production.

GlaxoSmithKline plc (ADR) (NYSE:GSK) had previously administered a six-minute walk test (how far a patient can walk in six minutes) to patients dosed with drisapersen, which was found to increase the boys’ average walking distance by 117 feet. Sarepta also beat Glaxo in that test as well, reporting an average walking distance increase of 152 feet with eteplirsen. However, investors should note that GlaxoSmithKline plc (ADR) (NYSE:GSK)’s testing group is significantly larger, with 53 boys, compared to the 12 tested in Sarepta’s studies.

Prosensa shareholders didn’t take the news too well, since drisapersen is the company’s most promising drug, and shares plunged 8% on Aug. 16. Glaxo was largely unaffected, but shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) climbed 3%. Sarepta intends to file an FDA approval for eteplirsen early next year, but doubts have been raised regarding its ambitious plans to receive an accelerated approval.

Either treatment is forecast to generate more than $1 billion in annual revenues if approved. Prosensa and GlaxoSmithKline plc (ADR) (NYSE:GSK) intend to release the full results of its Phase III trial later this year for drisapersen, and Sarepta is expected to start a Phase III trial for eteplirsen next year.

A newcomer carves out a new niche
Although Sarepta Therapeutics Inc (NASDAQ:SRPT), Prosensa, and Glaxo are currently the biggest names in DMD treatments now, that hasn’t discouraged smaller competitors from exploring their own treatments. One notable newcomer is PTC Therapeutics, which only went public two months ago. PTC recently initiated a phase 3 clinical trial of ataluren, a treatment for patients with nonsense mutation DMD.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.